Early viral load outperforms cytokines and lymphocytes in predicting SFTS prognosis: A dynamic immune profiling study.

Body weight and water temperature shape VHSV infection dynamics and shedding in olive flounder (Paralichthys olivaceus).

Evidence for triaging HPV-positive women using viral load: data from two large cohort-screening projects in different regions of China.

Mouthrinses differentially rewire salivary virus-microbiome interaction dynamics in COVID-19 patients: A randomized controlled trial.

Analytical techniques for laboratory testing of HIV: a systematic review.

Application of digital PCR and CRISPR/Cas13a-based fluorescent assay for accurate and on-site detection of cotton leafroll dwarf virus.

Collective versus individual amitraz treatments shape Varroa destructor infestation and viral load dynamics in honeybee colonies.

BK polyomavirus (BKPyV) is a common opportunistic infection in kidney transplant recipients, typically reactivating in the context of immunosuppression. Although asymptomatic in immunocompetent individuals, reactivation in transplant recipients can cause BKPyV-associated nephropathy (BKPyVAN), a leading cause of graft dysfunction and loss. BKPyV viremia affects approximately 10%-15% of transplant recipients, and once BKPyVAN is established, the risk of graft failure can exceed 50%. The current standard of care involves immunosuppression reduction to restore virus-specific immunity, but this approach increases the risk of acute and chronic rejection. Intravenous immunoglobulin (IVIg), which contains antiviral and immunomodulatory antibodies, has been proposed as an adjunctive therapy, although evidence supporting its efficacy remains limited to small observational studies. The BEAT-BK trial is a multicenter, adaptive, randomized controlled trial comparing standard immunosuppression reduction with or without IVIg in kidney and simultaneous pancreas-kidney transplant recipients with BKPyV viremia or biopsy-confirmed BKPyVAN. The trial will enroll participants aged 2 y and older, randomizing them 1:1 to receive standard care alone or in combination with a total IVIg dose of 2 g/kg for 8 wk. An adaptive Bayesian design will permit interim analyses with the potential for early trial success or futility. The primary endpoint is a composite ordinal outcome at 12 wk, incorporating death, graft loss, estimated glomerular filtration rate decline, acute rejection, viral load, and degree of immunosuppression reduction. Secondary outcomes include viral clearance, development of BKPyVAN and donor-specific antibodies, infections, malignancy, quality of life, and cost-effectiveness. This trial will provide the first high-quality evidence on the role of IVIg in BKPyV management and inform clinical decision-making in posttransplant care.

HIV-1 late diagnosis: Strategies to overcome the misclassification of individuals acutely infected with HIV-1 as individuals diagnosed late.

Patagonian shellfish and hidden threats: unveiling the viral landscape and the first quantitative microbial risk assessment of Argentine bivalve mollusks.

Age distribution of respiratory syncytial virus disease in children younger than 5 years in low-income and middle-income countries: a systematic review and meta-analysis.

Evaluation of Tasso T20 to collect dried blood for the quantification of HIV-1 RNA.

Guizhi Gegen Decoction alleviates influenza-associated intestinal injury by balancing lung-gut ILC2 distribution via the S1P/S1PR1 axis.

Spike 1 trimer subunit vaccines against porcine epidemic diarrhea virus effectively induce protective immunity challenge in piglets.

Luteolin exhibits broad-spectrum antiviral activity against swine enteric coronaviruses by targeting 3CLpro.

Establishment of an immortalized renal epithelial cell line derived from grass carp and its susceptibility to grass carp Reovirus genotype II.

Protective efficacy of a candidate attenuated live vaccine derived from an NADC30-like strain against homologous porcine reproductive and respiratory syndrome virus challenge.

A review of targeting microRNAs as potential therapeutic strategies against respiratory viruses: Current insights and future directions.

Immune and protective effects of recombinant multi-epitopes vaccine against infectious spleen and kidney necrosis virus in pearl gentian grouper (♀Epinephelus fuscoguttatus × ♂Epinephelus lanceolatus).

Inactivation of avian influenza virus in yogurt made from raw milk.